|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Additional conditions recognized in this trial | ||||
| Brain Neoplasms | |||||
| Central Nervous System Neoplasms | |||||
| Nervous System Neoplasms | |||||
| 2 | More general conditions related to this trial | ||||
| Brain Diseases | |||||
| Central Nervous System Diseases | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| Nervous System Diseases | |||||
| 3 | Interventions listed in this trial | ||||
| antineoplaston A10 | |||||
| antineoplaston AS2-1 | |||||
| 4 | Sponsors listed in this trial | ||||
| Burzynski Research Institute | |||||